Literature DB >> 11557117

Reduced expression of cell-cycle regulator p27(Kip1) correlates with a shortened survival in non-small cell lung cancer.

S Tsukamoto1, K Sugio, T Sakada, C Ushijima, K Yamazaki, K Sugimachi.   

Abstract

BACKGROUND: The cell cycle progression is governed by a family of cyclin-dependent kinases, which are regulated by associated cyclins and by phosphorylation. p27, a cyclin-dependent kinase inhibitor, regulates the progression from G1 into the S phase by binding and inhibiting cyclin/cdks. Although p27 mutations in human tumors are extremely rare, a reduced expression of p27 might to lead to a progression of cancer cells.
METHODS: We examined tissues that had been surgically excised from 161 unselected Japanese patients with non-small cell lung cancer, and investigated the p27 protein expression by immunohistochemistry.
RESULTS: A reduced expression of the p27 protein was found in 63 cases (39.0%). Statistical correlation was found between the reduced p27 expression and advanced stage, although no correlation was found between the level of p27 expression and the gender, T factor, N factor or histological differentiation. The 5-year survival rate in the reduced group was 35.4%, which was statistically poorer than the 63.2% rate in the normal group (P=0.0016), in patients with complete resection. In a multivariate analysis, the level of p27 expression was found to be an independent prognostic indicator.
CONCLUSIONS: We demonstrated the expression of p27 protein to be a biological prognostic indicator which can indicate the subsets of patients with either a good or poor prognosis, in patients who underwent surgical resection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557117     DOI: 10.1016/s0169-5002(01)00216-1

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

Review 1.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

2.  Association of cytoplasmic p27 expression with an unfavorable response to cisplatin-based chemotherapy and poor outcomes in non-small cell lung cancer.

Authors:  Tsang-Chi Lin; Lung-Hung Tsai; Ming-Chih Chou; Chih-Yi Chen; Huei Lee
Journal:  Tumour Biol       Date:  2015-10-20

3.  SIRT1 inactivation evokes antitumor activities in NSCLC through the tumor suppressor p27.

Authors:  Lijia Zhu; Christine Y Chiao; Katelyn G Enzer; Alexander J Stankiewicz; Douglas V Faller; Yan Dai
Journal:  Mol Cancer Res       Date:  2014-08-20       Impact factor: 5.852

Review 4.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

Review 5.  Role of cell cycle regulators in lung carcinogenesis.

Authors:  Beatrice Eymin; Sylvie Gazzeri
Journal:  Cell Adh Migr       Date:  2010-01-16       Impact factor: 3.405

Review 6.  [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].

Authors:  Sabine Danzinger; Martin Filipits
Journal:  Wien Med Wochenschr       Date:  2007

7.  A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis.

Authors:  Dali Chen; Longyong Mei; Yubin Zhou; Cheng Shen; Huan Xu; Zhongxi Niu; Guowei Che
Journal:  Oncol Lett       Date:  2015-01-15       Impact factor: 2.967

8.  Dual effects of Ral-activated pathways on p27 localization and TGF-β signaling.

Authors:  Keren Tazat; Meirav Harsat; Ayelet Goldshmid-Shagal; Marcelo Ehrlich; Yoav I Henis
Journal:  Mol Biol Cell       Date:  2013-04-10       Impact factor: 4.138

9.  UBAC2 promotes bladder cancer proliferation through BCRC-3/miRNA-182-5p/p27 axis.

Authors:  Chaohui Gu; Keyuan Zhao; Naichun Zhou; Feng Liu; Fei Xie; Shunli Yu; Yongjie Feng; Long Chen; Jinjian Yang; Fengyan Tian; Guosong Jiang
Journal:  Cell Death Dis       Date:  2020-09-10       Impact factor: 8.469

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.